John Stanford spent a busy day on…
John Stanford spent a busy day on Capitol Hill this [...]
John Stanford spent a busy day on Capitol Hill this [...]
Wave Life Sciences linked its obesity drug candidate to a [...]
Maze Therapeutics has revealed topline phase 2 data for its [...]
Merck and Terns Pharmaceuticals have agreed to a $6.7 billion [...]
Sarepta Therapeutics has shared initial clinical data on two siRNA [...]
Full 12-month data from Ocugen’s phase 2 eye disease gene [...]
Shionogi has struck a deal to take full control of [...]
Innovent Biologics’ eye disease prospect has matched Bayer and Regeneron’s [...]
Apogee Therapeutics has published phase 2 eczema data that suggest [...]
Sanofi has returned to T-cell engager territory via an agreement [...]